BRIEF published on 03/13/2025 at 09:07, 24 days 22 hours ago LAIQON AG prévoit une forte croissance dans un contexte de transformations stratégiques Croissance Financière LAIQON AG Gestion De Patrimoine Cession D'actifs Perspectives 2025
BRIEF published on 03/13/2025 at 09:07, 24 days 22 hours ago LAIQON AG Projects Strong Growth Amid Strategic Transformations Wealth Management Financial Growth LAIQON AG 2025 Outlook Asset Divestment
PRESS RELEASE published on 03/13/2025 at 09:02, 24 days 22 hours ago Original-Research: LAIQON AG (von NuWays AG): Buy Research update on LAIQON AG by NuWays AG highlights solid FY'24 performance, with 9.5% organic sales growth and positive outlook for FY'25. Emphasis on AuM scaling and profitability improvements NuWays AG Research Update LAIQON AG FY'24 Performance AuM Scaling
BRIEF published on 03/05/2025 at 08:19, 1 month 1 day ago Axel Hörger rejoint LAIQON AG en tant que Senior Advisor Expertise Financière LAIQON AG Initiatives De Croissance Gestion De Patrimoine Axel Hörger
BRIEF published on 03/05/2025 at 08:19, 1 month 1 day ago Axel Hörger Joins LAIQON AG as Senior Advisor Financial Expertise Wealth Management LAIQON AG Growth Initiatives Axel Hörger
PRESS RELEASE published on 03/05/2025 at 08:14, 1 month 1 day ago LAIQON AG: Axel Hörger, former CEO of UBS Deutschland AG, is Senior Advisor to the Board Axel Hörger, former CEO of UBS Deutschland AG, joins LAIQON AG as Senior Advisor to the Board, bringing three decades of financial sector experience Wealth Management LAIQON AG Senior Advisor Axel Hörger UBS Deutschland AG
BRIEF published on 12/03/2024 at 13:26, 4 months 3 days ago La Fondation Joachim Herz investit dans LAIQON AG Croissance À Long Terme Fondation Joachim Herz Investissement De LAIQON AG Filiale De WealthTech Partenariats Financiers
BRIEF published on 12/03/2024 at 13:26, 4 months 3 days ago Joachim Herz Foundation Invests in LAIQON AG Long-term Growth Joachim Herz Foundation LAIQON AG Investment WealthTech Subsidiary Financial Partnerships
PRESS RELEASE published on 12/03/2024 at 13:21, 4 months 3 days ago Original-Research: LAIQON AG (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates LAIQON AG classification to BUY with a target price of €9.80 as Joachim Herz Foundation becomes a new anchor investor, supporting long-term growth and innovation First Berlin Equity Research Long-term Growth LAIQON AG BUY Joachim Herz Foundation
BRIEF published on 09/12/2024 at 14:36, 6 months 24 days ago First Berlin Equity Research Reiterates Buy Rating for LAIQON AG Financial Results BUY Rating Target Price Assets Under Management LAIQON AG
Published on 04/07/2025 at 00:05, 7 hours 33 minutes ago Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders
Published on 04/05/2025 at 01:50, 2 days 5 hours ago Battery X Metals Achieves Graphite Recovery Breakthrough in Partnership with Global Top 20 University in Controlled Trials
Published on 04/07/2025 at 07:03, 35 minutes ago Swiss Re to be appointed as co-investment manager of GAM's catastrophe bond and ILS fund range
Published on 04/07/2025 at 07:00, 37 minutes ago Julius Baer further streamlines its organisation to reinforce focus on clients and sustainable growth
Published on 04/06/2025 at 18:20, 13 hours 17 minutes ago EQS-Adhoc: QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook
Published on 04/06/2025 at 15:09, 16 hours 29 minutes ago EQS-Adhoc: DEUTZ acquires developer of electrification solutions UMS
Published on 04/04/2025 at 19:00, 2 days 12 hours ago PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 04/07/2025 at 07:01, 37 minutes ago bioMérieux obtient le marquage CE pour LUMED™ APSS™, une solution logicielle de pointe pour aider à prendre des décisions en matière de bon usage des antibiotiques
Published on 04/07/2025 at 07:01, 37 minutes ago bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship
Published on 04/04/2025 at 19:18, 2 days 12 hours ago Mersen: Number of shares and voting rights as of March 31, 2025
Published on 04/04/2025 at 19:18, 2 days 12 hours ago Mersen : nombre d'actions et de droits de vote au 31 mars 2025
Published on 04/04/2025 at 18:17, 2 days 13 hours ago Reporting on share buyback transactions carried out between March 31 and April 3, 2025
